We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel X-Linked Intellectual Disability Genes Identified

By LabMedica International staff writers
Posted on 24 Feb 2015
A novel group of genes on the X-chromosome that when mutated lead to the mental disorder X-linked intellectual disability (XLID) have been added to list of more than a 100 such genes that had been identified previously.

XLID is a generalized neurodevelopmental disorder characterized by significantly impaired intellectual and adaptive functioning. More...
It is defined by an IQ score below 70 in addition to deficits in two or more adaptive behaviors that affect everyday general living. The syndrome is caused by mutations on the X-chromosome. Since males have only one X-chromosome and the syndrome is passed on in a recessive manner, the disorder mainly occurs in boys. Over the past 20 years more than 100 X-chromosome genes linked to XLID have been found. Nonetheless, intellectual disabilities that map to the X-chromosome remain unresolved in a large number of families, which suggests that more XLID genes or loci are yet to be identified.

To identify more XLID-linked genes investigators at the Max Planck Institute for Molecular Genetics (Berlin, Germany) employed massively parallel sequencing of all X-chromosome exons in the index males of 405 families with XLID of unknown origin. In total, 745 X-chromosomal genes were screened.

Results revealed that 80 families (20%) carried pathogenic variants in established XLID genes. In 19 families, the investigators detected likely causative protein truncating and missense variants in seven novel and validated XLID genes (CLCN4, CNKSR2, FRMPD4, KLHL15, LAS1L, RLIM, and USP27X) and potentially deleterious variants in two novel candidate XLID genes (CDK16 and TAF1). Furthermore, they showed that the CLCN4 and CNKSR2 variants impaired protein functions as indicated by electrophysiological studies and altered differentiation of cultured primary neurons from mice lacking CLCN4 or after mRNA knock-down.

"In addition to known disease-related genes, we have discovered seven novel genes as the cause of X-linked intellectual disability and analyzed what signaling pathways in the cells each protein is involved in," said senior author Dr. Vera Kalscheuer, professor of human molecular genetics at the Max Planck Institute for Molecular Genetics. "The clinical presentation and severity of the disorder depend on the responsible gene and the nature of the mutation."

The study was published in the February 3, 2015, online edition of the journal Molecular Psychiatry.

Related Links:

Max Planck Institute for Molecular Genetics



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.